MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vaccine.2026.128536

Медицинская библиотека · Vaccine · 2026

Cost and effectiveness of COVID-19 vaccination strategies during the 2023 post-reopening omicron wave in Xinjiang, Western China: Evidence from SIR and Markov models.

Wu Di, Liu Kejun

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

COVID-19 vaccination reduces infection, hospitalization, and mortality. While many countries rely on mRNA vaccines, China predominantly uses inactivated and recombinant protein vaccines. This study evaluated the cost-effectiveness of multidose COVID-19 vaccination strategies during the 2023 post-reopening Omicron wave in China (characterized by high prior vaccination coverage and reduced severity compared with earlier variants) using region-specific cost data from Xinjiang, Western China.

METHODS

A Markov decision model based on the Susceptible-Infectious-Recovered framework compared three strategies during the 2023 post-zero-COVID Omicron wave in China: 1) three doses of an inactivated vaccine (one-dose booster vaccination), 2) three doses of an inactivated vaccine plus one dose of a recombinant protein vaccine (two-dose booster vaccination), and 3) three doses of an inactivated vaccine plus one dose of an mRNA vaccine (two-dose booster vaccination). The analysis adopted a societal perspective. Primary outcomes included quality-adjusted life years (QALYs) and deaths averted. Cost and epidemiological parameters were derived from field surveys, cost accounting, and a literature review. One-way and probabilistic sensitivity analyses addressed robustness.

RESULTS

The estimated treatment costs for mild, moderate, and severe COVID-19 cases were approximately CNY 15, CNY 643, and CNY 7143, respectively. The per-dose vaccination cost (excluding vaccine price) was CNY 55.19. Strategy 2 yielded 462,800 QALYs at a total cost of CNY 6.552 billion, with an incremental cost-utility ratio of CNY 18,404.23 per QALY compared to Strategy 1 (0.70 x per capita GDP). Strategy 3 had an ICER of CNY 28,472.60 per QALY (0.32 x per capita GDP) and provided greater health benefits at a lower total cost.

CONCLUSIONS

Heterologous multidose booster vaccinations, particularly with mRNA-based regimens, were a cost-effective strategy under the epidemiological conditions of the 2023 Omicron-dominant post-reopening phase in China. Optimizing vaccine booster selection may improve economic efficiency and public health preparedness.

Для цитирования: Wu Di, Liu Kejun. Cost and effectiveness of COVID-19 vaccination strategies during the 2023 post-reopening omicron wave in Xinjiang, Western China: Evidence from SIR and Markov models.. Vaccine. 2026. DOI: 10.1016/j.vaccine.2026.128536.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.